Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335581 · ClinicalTrials.gov registry record · NA
Study of Laser Treatment of Melasma
A NA study of Refractory Mixed Type Melasma, sponsored by ConBio, a Cynosure Company.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01335581: Completed NA study of Refractory Mixed Type Melasma, sponsored by ConBio, a Cynosure Company.
NCT01335581 is a NA study of Refractory Mixed Type Melasma that has completed, run by ConBio, a Cynosure Company. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01335581, a NA study of Refractory Mixed Type Melasma, has completed, sponsored by ConBio, a Cynosure Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
Primary Outcome
The severity of the melasma is assessed based on a photographic scale. The scale ranges from 0 to 48, with 48 being the most severe. A decrease in the MASI score from the baseline to the follow up corresponds with decreasing severity.
Conditions Studied
Interventions
- DEVICE Q-Switched Nd:YAG Laser (RevLite)
- DRUG Retin-A and microdermabrasion
Study Locations (1)
New York
- New York Laser and Skin Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT01335581 record still lists
NCT01335581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Refractory Mixed Type Melasma appearing as the primary indexed condition, and to 2 interventions - of which Q-Switched Nd:YAG Laser (RevLite) is the first listed.
NCT01335581 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01335581 about?
NCT01335581 is a clinical study titled "Study of Laser Treatment of Melasma". The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
What is the current status of trial NCT01335581?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2011-04. Estimated completion is 2012-03.
What conditions does trial NCT01335581 study?
This clinical trial studies the following conditions: Refractory Mixed Type Melasma.
What interventions are being tested in trial NCT01335581?
The interventions under investigation include: Q-Switched Nd:YAG Laser (RevLite) (DEVICE), Retin-A and microdermabrasion (DRUG).
Who is sponsoring clinical trial NCT01335581?
This trial is sponsored by ConBio, a Cynosure Company, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01335581 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01335581's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia